CA2000893A1 - Lipoproteine ayant une activite biologique et son application - Google Patents

Lipoproteine ayant une activite biologique et son application

Info

Publication number
CA2000893A1
CA2000893A1 CA2000893A CA2000893A CA2000893A1 CA 2000893 A1 CA2000893 A1 CA 2000893A1 CA 2000893 A CA2000893 A CA 2000893A CA 2000893 A CA2000893 A CA 2000893A CA 2000893 A1 CA2000893 A1 CA 2000893A1
Authority
CA
Canada
Prior art keywords
lipoprotein
pharmaceutical composition
biologically active
patient
active lipoprotein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2000893A
Other languages
English (en)
Other versions
CA2000893C (fr
Inventor
Tore Curstedt
Hans Jornvall
Bjorn Lowenadler
Bengt Robertsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Swedish Orphan Biovitrum AB
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20373667&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2000893(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2000893A1 publication Critical patent/CA2000893A1/fr
Application granted granted Critical
Publication of CA2000893C publication Critical patent/CA2000893C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002000893A 1988-10-18 1989-10-17 Lipoproteine ayant une activite biologique et son application Expired - Fee Related CA2000893C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE19888803713A SE8803713D0 (sv) 1988-10-18 1988-10-18 Biologically active lipoprotein and its use
SE8803713-0 1988-10-18

Publications (2)

Publication Number Publication Date
CA2000893A1 true CA2000893A1 (fr) 1990-04-18
CA2000893C CA2000893C (fr) 2000-08-08

Family

ID=20373667

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002000893A Expired - Fee Related CA2000893C (fr) 1988-10-18 1989-10-17 Lipoproteine ayant une activite biologique et son application

Country Status (8)

Country Link
US (2) US5223481A (fr)
EP (1) EP0368823B2 (fr)
JP (1) JP2963923B2 (fr)
AT (1) ATE84799T1 (fr)
AU (1) AU623180B2 (fr)
CA (1) CA2000893C (fr)
DE (1) DE68904530T3 (fr)
SE (1) SE8803713D0 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3888823T2 (de) * 1987-09-01 1994-08-11 Teijin Ltd Verfahren zum testen einer wirksamen substanz die sich auf der oberfläche menschlicher lungen befindet.
SE8803713D0 (sv) * 1988-10-18 1988-10-18 Kabigen Ab Biologically active lipoprotein and its use
JPH04506809A (ja) * 1989-07-11 1992-11-26 ジェネンテク，インコーポレイテッド 界面活性剤組成物および方法
CA2063273C (fr) * 1989-07-11 2002-09-24 Bradley J. Benson Surfactants pulmonaires et methodes
DE69125750D1 (de) * 1990-05-21 1997-05-28 Abbott Lab Fettsäure-Oberflächenaktives-Lungenprotein Konjate
US5258496A (en) * 1990-07-10 1993-11-02 Scios Nova Inc. Isolation and purification of lung surfactant protein
US5272252A (en) * 1991-11-04 1993-12-21 Merrell Dow Pharmaceuticals Inc. Synthetic lung surfactant having antioxidant properties
JP3961029B2 (ja) * 1992-06-24 2007-08-15 博 木戸 インフルエンザウィルス感染防止剤
PT733645E (pt) * 1993-12-08 2003-07-31 Mitsubishi Pharma Corp Novo peptido sintetico tensoactivo pulmonar que o contem e medicamento para sindroma da insuficiencia respiratoria
DE4418936A1 (de) * 1994-05-31 1996-02-08 Byk Gulden Lomberg Chem Fab Polypeptid
FR2739860B1 (fr) * 1995-10-17 1998-01-02 Coletica Complexes amphiphiles, procede pour leur preparation et compositions en renfermant
ATE301674T1 (de) * 1996-05-15 2005-08-15 Altana Pharma Ag Verfahren zur trennung und bestimmung von hydrophoben proteinen durch dünnschichtchromatographie
US6476191B1 (en) 1999-02-05 2002-11-05 Mixture Sciences, Inc. Volatilizable solid phase supports for compound synthesis
IT1308180B1 (it) * 1999-02-12 2001-12-07 Chiesi Farma Spa Peptidi sintetici aventi la capacita' di diminuire la tensionesuperficiale e loro impiego nella preparazione di un surfattante
AU6083899A (en) 1999-09-16 2001-04-17 Aventis Behring Gmbh Combination of c1-inh and lung surfactant for the treatment of respiratory disorders
DE50214446D1 (de) 2001-10-11 2010-07-01 Nycomed Gmbh Neue verwendung von lungensurfactant
JP5108515B2 (ja) 2004-08-06 2012-12-26 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 肺サーファクタント及びｔｎｆ由来ペプチドを含有する組成物
US7464012B2 (en) * 2004-12-10 2008-12-09 L'air Liquide, Societe Anonyme A Directoire Et Conseil De Surveillance Pour L'etude Et L'exploitation Des Procedes Georges Claude Simplified process simulator
US7582312B2 (en) 2004-11-15 2009-09-01 Discovery Laboratories, Inc. Methods to produce lung surfactant formulations via lyophilization and formulations and uses thereof
EP2298349A1 (fr) 2005-01-06 2011-03-23 Discovery Laboratories, Inc. Schéma de traitment utilisant un surfactant pour la prévention ou traitment de la dysplasie boncho-pulmonaire
JP2007309695A (ja) * 2006-05-16 2007-11-29 Univ Of Tokyo 質量分析のための脂質修飾ペプチドの抽出方法
WO2008036293A1 (fr) * 2006-09-19 2008-03-27 Discovery Laboratories, Inc. Formulations de surfactant pulmonaire et procédés favorisant l'élimination du mucus
US7951781B2 (en) 2006-11-02 2011-05-31 University Of Iowa Research Foundation Methods and compositions related to PLUNC surfactant polypeptides
CN101754747A (zh) * 2007-06-05 2010-06-23 Paka肺部医药公司 用于向肺脏递送药物的方法以及组合物
EP2370068A4 (fr) 2008-12-10 2015-09-23 Paka Pulmonary Pharmaceuticals Inc Procédés et compositions pour la délivrance de médicaments aux poumons
WO2013188016A2 (fr) 2012-05-04 2013-12-19 Discovery Laboratories, Inc. Thérapie utilisant des surfactants pour exposition à un rayonnement ionisant

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4234475A (en) * 1975-08-15 1980-11-18 The Gillette Company Reacting protein with organic acid
DE2925942A1 (de) * 1979-06-27 1981-01-22 Bayer Ag Disazokupferkomplex-reaktivfarbstoffe
US4406833A (en) * 1982-06-04 1983-09-27 Fats And Proteins Research Foundation, Inc. Surfactants derived from fatty acid esters and proteinaceous material
US4933280A (en) * 1984-12-11 1990-06-12 California Biotechnology Inc. Recombinant DNA sequence encoding Alveolar Surfactant Protein
US4659805A (en) * 1984-12-11 1987-04-21 California Biotechnology, Inc. Recombinant alveolar surfactant protein
US4882422A (en) * 1985-10-24 1989-11-21 Genetics Institute, Inc. Pulmonary surfactant proteins
US4918161A (en) * 1985-09-26 1990-04-17 Genetics Institute, Inc. Low molecular weight pulmonary surfactant proteins
JPS63503222A (ja) * 1986-05-06 1988-11-24 サイオス　ノバ　インコーポレイテッド 肺の疎水性界面活性物質に結合した分子量６，０００ダルトンのタンパク質及びその多量体
US5013720A (en) * 1986-05-06 1991-05-07 Abbott Laboratories SAP-6-Val proteins and methods
EP0290516A4 (fr) * 1986-10-24 1989-11-14 Jeffrey A Whitsett Proteines associees a des agents tensioactifs hydrophobes pulmonaires.
JPH01501282A (ja) * 1986-12-08 1989-05-11 ホイツトセツト，ジエフリー　エイ． 肺胞疎水性界面活性物質関連タンパク質
IT1203873B (it) * 1987-04-08 1989-02-23 Chiesi Farma Spa Composizioni farmaceutiche che lo surfattante polmonare naturale, contengono. metodo di preparazione e
AU1996388A (en) * 1987-07-01 1989-01-30 Kabigen Ab Proteins and protein compositions and their use
US4861756A (en) * 1988-03-08 1989-08-29 Merrell Dow Pharmaceuticals Inc. Synthetic pulmonary surfactant
SE8803713D0 (sv) * 1988-10-18 1988-10-18 Kabigen Ab Biologically active lipoprotein and its use
US4993280A (en) * 1989-07-17 1991-02-19 Motorola, Inc. Rotational control assembly

Also Published As

Publication number Publication date
DE68904530T3 (de) 1999-07-08
JPH02145599A (ja) 1990-06-05
US5223481A (en) 1993-06-29
ATE84799T1 (de) 1993-02-15
DE68904530T2 (de) 1993-07-29
JP2963923B2 (ja) 1999-10-18
CA2000893C (fr) 2000-08-08
DE68904530D1 (de) 1993-03-04
EP0368823B2 (fr) 1998-12-23
SE8803713D0 (sv) 1988-10-18
AU4299689A (en) 1990-04-26
EP0368823A2 (fr) 1990-05-16
EP0368823A3 (en) 1990-05-23
US5455227A (en) 1995-10-03
AU623180B2 (en) 1992-05-07
EP0368823B1 (fr) 1993-01-20

Similar Documents

Publication Publication Date Title
AU4299689A (en) Biologicaly active lipoprotein and its use
US4692433A (en) Method and composition for regulating serum calcium levels of mammals
DE69901284T2 (de) Transnasaler Transport bzw. Impfung mit hochadaptierbaren Trägern
KR100381643B1 (ko) 수면 무호흡증을 치료하기 위한 약제학적 조성물
PL306576A1 (en) Skin moistening composition effective in respect to both superficial and deep layer of human skin and application of such composition
RU97102349A (ru) Композиция для получения лекарственного средства (варианты) и способ ее получения
CA2093806A1 (fr) Methode de traitement ou de prevention du diabete de type 1 par l'administration orale d'insuline
CA2285203A1 (fr) Compositions contenant de la capsaicine ou des analogues de capsaicine et un anesthesique local
GB9316895D0 (en) Hepatoselective insulin analogues
AU562676B2 (en) Surfactants having pulmonary surface activity
GR20010300075T1 (en) Reduction of liposome-induced adverse physiological reactions
BR9507811B1 (pt) polipeptìdeos e composição farmacêutica.
EP0177342A3 (fr) Formulations orales de protéines thérapeutiques
AU3904193A (en) Liposome composition
DE69901314T2 (de) Insulin präparationen enthaltend methanol zur pulmonaren verabreichung
AU7284098A (en) Method for preventing gastritis using amylin or amylin agonists
AU3037089A (en) Lipid metabolism improving agent and method of its use
BE894188A (fr) Formulations pharmaceutiques comprenant de l'insuline et de la pro-insuline humaine
EP1264612A1 (fr) Méthode pour l'administration nasale d'un médicament
FR2513126B1 (fr) Formulations pharmaceutiques comprenant de l'insuline humaine et du c-peptide humain
ATE183651T1 (de) Verwendung von wachstumsfaktor igf-ii zur beahandlung von gastrointestinalen störungen
DE69132211D1 (de) Synthetische oberflächenaktive agentien auf der lunge
IL95892A0 (en) Aroyl-ureas,their preparation and pharmaceutical compositions containing them
ES2092969A1 (es) Surfactante pulmonar natural de origen porcino.
GB8804188D0 (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed